Picture loading failed.

Anti-CD22 therapeutic antibody (Pre-made Moxetumomab biosimilar,Fv Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Moxetumomab pasudotox-tdfk injection is used to treat hairy cell leukemia that has worsened or cannot be completely removed in patients who have had at least two previous treatments that did not work well.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-358-1mg 1mg Inquiry
GMP-Bios-ab-358-10mg 10mg Inquiry
GMP-Bios-ab-358-100mg 100mg Inquiry
GMP-Bios-ab-358-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD22 therapeutic antibody (Pre-made Moxetumomab biosimilar,Fv Fusion)
INN Name Moxetumomab
TargetCD22
FormatFv Fusion
Derivation
Species ReactivityHuman
CH1 Isotypena
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesNational Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA)
Conditions ApprovedHairy cell leukaemia
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma
Development TechCAT Phage Display